So much so that a neutralizing anti-CD40L mAbs (clone IDEC-131) showed promising results in inhibiting MS relapses during clinical trials, but the trial was halted due to severe thromboembolism in a patient with Crohn’s disease[67]. This evidence concerns the gene CD40LG and myeloid sarcoma.